Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Epigenetic Modifications of the Bone Marrow (BM) Niche in Multiple Myeloma (MM) - a Three-Dimensional (3D) in Vitro Approach

Stefan J. Müller, PharmD, Dagmar Wider, Andreas R. Thomsen, MD, Marie Follo, PhD, Johannes M. Waldschmidt, MD, Gabriele Ihorst, Sandra M. Dold, MSc, Julia Felthaus, Johanna Senger, PhD, Julia Schüler, DVM, Justus Duyster, Abdel Kareem Azab, PhD, Martin J. Hug, PhD, Manfred Jung, PhD, Ralph Wäsch, MD, Monika Engelhardt

Blood (2017) 130 (Supplement 1): 1793.

https://doi.org/10.1182/blood.V130.Suppl_1.1793.1793

Published: 2017

Journal Articles

Testing Novel Anti - Multiple Myeloma (MM) Agents in a Suitable Three-Dimensional (3D) Co-Culture Platform

Stefan J. Müller, Dipl.-Pharm., Johannes M. Waldschmidt, MD, Johanna Senger, PhD, Dagmar Wider, Andreas R. Thomsen, MD, Gabriele Ihorst, PhD, Justus Duyster, MD, Martin J. Hug, PhD, Manfred Jung, PhD, Ralph Wäsch, MD, Monika Engelhardt, MD PhD

Blood (2016) 128 (22): 2109.

https://doi.org/10.1182/blood.V128.22.2109.2109

Published: 2016

Journal Articles

Lenalidomide Inhibits Thioredoxin Reductase (TrxR) in Multiple Myeloma (MM) Cells but Direct Inhibition of Trxr and Thioredoxin (Trx) Can Bypass Requirement of Cereblon (CRBN)

Sinto Sebastian Chirackal, PhD, Esteban Braggio, PhD, Yuan Xiao Zhu, PhD, Chang-Xin Shi, PhD, Scott Van Wier, Gregory Ahmann, Veronica Gonzalez-Calle, MD, Marta Chesi, PhD, Leif Bergsagel, MD, Keith Stewart, M.B., Ch.B., Rafael Fonseca, MD

Blood (2016) 128 (22): 4482.

https://doi.org/10.1182/blood.V128.22.4482.4482

Published: 2016

Journal Articles

Preclinical activity of the repurposed drug auranofin in classical Hodgkin lymphoma

Marta Celegato, Cinzia Borghese, Naike Casagrande, Maurizio Mongiat, Xaver U. Kahle, Alice Paulitti, Michele Spina, Alfonso Colombatti, Donatella Aldinucci

Blood (2015) 126 (11): 1394–1397.

https://doi.org/10.1182/blood-2015-07-660365

Published: 2015

Includes: Supplemental data

Journal Articles

Auranofin Induces a Reversible In-Vivo Stress Response That Correlates With a Transient Clinical Effect In Patients With Chronic Lymphocytic Leukemia

Nakhle S Saba, MD, Mondana Ghias, Rekha Manepalli, Kevin Schorno, MBA, Scott Weir, PharmD, PhD, Christopher Austin, MD, Kami Maddocks, John C. Byrd, MD, Suman Kambhampati, MD, Kapil Bhalla, MD, Adrian Wiestner, MD, PhD

Blood (2013) 122 (21): 3819.

https://doi.org/10.1182/blood.V122.21.3819.3819

Published: 2013

Journal Articles

The Rheumatoid Arthritis Drug Auranofin Has Significant in Vitro Activity in MCL and DLCL and Is Synergistic with a Glutathione Depleting Agent

Jolanta Skalska, PhD, Michelle M. Kiebala, PhD, Shannon P. Hilchey, PhD, Yun Dai, MD, PhD, Steven Grant, MD, Paul S. Brookes, PhD, Derick R. Peterson, PhD, Sanjay B. Maggirwar, PhD, Steven H. Bernstein, MD

Blood (2012) 120 (21): 1658.

https://doi.org/10.1182/blood.V120.21.1658.1658

Published: 2012

Journal Articles

The Gold Compound Auranofin Induces Oxidative Stress and Apoptosis in Primary CLL Cells Independent of Classic Prognostic Markers and the Protective Effect of the Tissue Microenvironment

Nakhle Saba, MD, Min Shen, PhD, Mondana Ghias, Mohammed Farooqui, DO, Christopher Austin, MD, Kevin Schorno, MBA, Scott Weir, PharmD, PhD, Kapil Bhalla, MD, Adrian Wiestner, MD, PhD

Blood (2012) 120 (21): 865.

https://doi.org/10.1182/blood.V120.21.865.865

Published: 2012

Journal Articles

Treatment with Auranofin Induces Oxidative and Lethal Endoplasmic Reticulum (ER) Stress Exerting Single Agent Activity Against Primary CLL Cells

Rekha Rao, PhD, Kami Maddocks, MD, Amy J. Johnson, PhD, Lata Chauhan, PhD, Suman Kambhampati, MD, Siddhartha Ganguly, MD, Ruben Reyes, MD, Omar S. Aljitawi, MD, Kevin Schorno, MBA, Kendra Ford, MSN, RN, CCRC, Eileen Dickman, PhD, MBA, John C. Byrd, MD, Kapil N. Bhalla, MD

Blood (2011) 118 (21): 929.

https://doi.org/10.1182/blood.V118.21.929.929

Published: 2011

Journal Articles

Gold Compound Auranofin (RIDAURA®) Induces Apoptosis of Human Myeloma Cells by Targeting STAT3 and NF-κB Pathways, with Clinical Potential.

Morihiko Sagawa, MD, Aya Nakaya, MD, Tatsuki Tomikawa, MD, Yuichiro Haba, MD, Tomoe Nemoto, MD, Kyoko Hanzawa, MD, Reiko Watanabe, MD, Michihide Tokuhira, MD, Shigehisa Mori, MD, Hideo Uchida, MD, Akihiro Muto, MD, PhD, Masahiro Kizaki, MD, PhD

Blood (2009) 114 (22): 3837.

https://doi.org/10.1182/blood.V114.22.3837.3837

Published: 2009

NARROW

Epigenetic Modifications of the Bone Marrow (BM) Niche in Multiple Myeloma (MM) - a Three-Dimensional (3D) in Vitro Approach

Testing Novel Anti - Multiple Myeloma (MM) Agents in a Suitable Three-Dimensional (3D) Co-Culture Platform

Lenalidomide Inhibits Thioredoxin Reductase (TrxR) in Multiple Myeloma (MM) Cells but Direct Inhibition of Trxr and Thioredoxin (Trx) Can Bypass Requirement of Cereblon (CRBN)

Preclinical activity of the repurposed drug auranofin in classical Hodgkin lymphoma

Auranofin Induces a Reversible In-Vivo Stress Response That Correlates With a Transient Clinical Effect In Patients With Chronic Lymphocytic Leukemia

The Rheumatoid Arthritis Drug Auranofin Has Significant in Vitro Activity in MCL and DLCL and Is Synergistic with a Glutathione Depleting Agent

The Gold Compound Auranofin Induces Oxidative Stress and Apoptosis in Primary CLL Cells Independent of Classic Prognostic Markers and the Protective Effect of the Tissue Microenvironment

Treatment with Auranofin Induces Oxidative and Lethal Endoplasmic Reticulum (ER) Stress Exerting Single Agent Activity Against Primary CLL Cells

Gold Compound Auranofin (RIDAURA®) Induces Apoptosis of Human Myeloma Cells by Targeting STAT3 and NF-κB Pathways, with Clinical Potential.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only